STOCK TITAN

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

UNITY Biotechnology [UBX] reported Q3 2024 financial results, highlighting progress in developing UBX1325 (foselutoclax) for diabetic macular edema (DME). Following FDA interaction, UNITY expects a pivotal study to be a non-inferiority trial comparing UBX1325 to aflibercept. Financial highlights include cash position of $29.0 million as of September 30, 2024, net loss of $6.5 million (down from $14.8 million in Q3 2023), and reduced R&D expenses of $2.8 million (down from $4.6 million). The company expects topline 24-week data in Q1 2025 and 36-week data in Q2 2025.

UNITY Biotechnology [UBX] ha riportato i risultati finanziari del terzo trimestre del 2024, evidenziando i progressi nello sviluppo di UBX1325 (foselutoclax) per l'edema maculare diabetico (DME). Dopo l'interazione con la FDA, UNITY prevede che uno studio cruciale sia un trial di non inferiorità che confronterà UBX1325 con aflibercept. Risultati finanziari includono una posizione di cassa di 29,0 milioni di dollari al 30 settembre 2024, una perdita netta di 6,5 milioni di dollari (in calo rispetto ai 14,8 milioni di dollari del Q3 2023) e spese di R&S ridotte a 2,8 milioni di dollari (in calo dai 4,6 milioni). L'azienda prevede dati preliminari a 24 settimane nel Q1 2025 e dati a 36 settimane nel Q2 2025.

UNITY Biotechnology [UBX] informó los resultados financieros del tercer trimestre de 2024, destacando los avances en el desarrollo de UBX1325 (foselutoclax) para el edema macular diabético (DME). Tras la interacción con la FDA, UNITY espera que un estudio pivotal sea un ensayo de no inferioridad que compare UBX1325 con aflibercept. Aspectos financieros incluyen una posición de efectivo de 29,0 millones de dólares al 30 de septiembre de 2024, una pérdida neta de 6,5 millones de dólares (decremento respecto a los 14,8 millones de dólares del Q3 2023), y gastos en I+D reducidos a 2,8 millones de dólares (bajados de 4,6 millones). La compañía espera datos iniciales a 24 semanas en el Q1 2025 y datos a 36 semanas en el Q2 2025.

UNITY Biotechnology [UBX]는 2024년 3분기 재무 결과를 발표하며 당뇨병 황반부종(DME)을 위한 UBX1325(포셀루토클락스) 개발의 진행 상황을 강조했습니다. FDA와의 상호작용 이후, UNITY는 중요한 연구가 UBX1325와 아플리버셉트를 비교하는 비열등성 시험이 될 것으로 기대하고 있습니다. 재무 하이라이트에는 2024년 9월 30일 기준으로 2,900만 달러의 현금 보유, 650만 달러의 순손실(2023년 3분기 1,480만 달러에서 감소) 및 280만 달러로 감소한 연구개발 비용(460만 달러에서 하락)이 포함됩니다. 이 회사는 2025년 1분기에 24주 데이터, 2025년 2분기에 36주 데이터를 기대하고 있습니다.

UNITY Biotechnology [UBX] a rapporté les résultats financiers du troisième trimestre 2024, soulignant les progrès dans le développement d'UBX1325 (foselutoclax) pour l'œdème maculaire diabétique (DME). Suite à une interaction avec la FDA, UNITY s'attend à ce qu'une étude clé soit un essai de non-infériorité comparant UBX1325 à aflibercept. Points financiers incluent une position de trésorerie de 29,0 millions de dollars au 30 septembre 2024, une perte nette de 6,5 millions de dollars (en baisse par rapport à 14,8 millions de dollars au T3 2023) et des dépenses de R&D réduites à 2,8 millions de dollars (en baisse par rapport à 4,6 millions). La société s'attend à des données préliminaires de 24 semaines au T1 2025 et des données à 36 semaines au T2 2025.

UNITY Biotechnology [UBX] hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht und dabei Fortschritte bei der Entwicklung von UBX1325 (Foselutoclax) zur Behandlung von diabetischem Makulaödem (DME) hervorgehoben. Nach der Interaktion mit der FDA erwartet UNITY, dass eine zentrale Studie ein Nichtunterlegenheitsstudie sein wird, die UBX1325 mit Aflibercept vergleicht. Finanzielle Highlights umfassen einen Kassenstand von 29,0 Millionen US-Dollar zum 30. September 2024, einen Nettoverlust von 6,5 Millionen US-Dollar (ein Rückgang von 14,8 Millionen US-Dollar im Q3 2023) und reduzierte F&E-Ausgaben von 2,8 Millionen US-Dollar (von 4,6 Millionen US-Dollar gesenkt). Das Unternehmen erwartet in Q1 2025 erste Daten nach 24 Wochen und in Q2 2025 Daten nach 36 Wochen.

Positive
  • Net loss decreased significantly from $14.8M to $6.5M year-over-year
  • Operating expenses reduced with R&D costs down by $1.8M and G&A expenses down by $0.5M
  • Cash burn rate improved with $15.0M used in operations vs $29.5M in previous year
Negative
  • Cash position declined from $43.2M to $29.0M since December 2023
  • Current cash runway only extends into Q3 2025

Insights

The Q3 2024 results reveal concerning financial metrics for UNITY Biotechnology. $29.0M in cash reserves represents a significant 32.9% decline from $43.2M at year-end 2023. While the net loss improved to $6.5M from $14.8M year-over-year, this was primarily achieved through cost-cutting measures including workforce reductions, rather than revenue growth.

The company's cash runway extends only into Q3 2025, which may be insufficient to fully support the ongoing Phase 2b ASPIRE study through completion and potential pivotal trial initiation. The reduced R&D spending of $2.8M, down from $4.6M, raises questions about the company's ability to maintain robust clinical development without additional financing.

The Phase 2b ASPIRE study design for UBX1325 shows strategic positioning against aflibercept, the current standard of care in DME. The FDA's guidance for a non-inferiority trial with a 4-letter margin on the ETDRS scale provides a clear regulatory pathway. However, the timeline for topline data extending into Q1 2025 puts pressure on the company's cash reserves.

The novel senolytic mechanism of UBX1325 could address significant unmet needs in DME treatment, particularly regarding treatment burden and sub-optimal responses. Yet, the reduction in R&D spending may impact the depth and scope of clinical development activities, potentially affecting the robustness of trial execution.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024.

“As recently discussed on our Ophthalmology Day for investors and analysts, diabetic macular edema represents a large underserved market due to inadequate response to anti-VEGF standard of care, continued vision loss over time despite treatment, and high treatment burden leading to discontinuation,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “We believe that UBX1325 (foselutoclax) with its novel mechanism of action has the potential to improve long-term visual outcomes for DME patients, via a proven and safe intravitreal route of administration. We believe that the readouts from the Phase 2b ASPIRE study comparing UBX1325 to the aflibercept standard of care will provide a definitive dataset to inform the design of a potential pivotal study.”

In the third quarter of 2024, UNITY had a Type C interaction with the U.S. Food and Drug Administration, or FDA, regarding the development of UBX1325 (foselutoclax) for DME. Based on that interaction, UNITY expects that a pivotal study would need to be a non-inferiority trial comparing UBX1325 to an approved anti-VEGF agent such as aflibercept. The endpoint for regulatory approval is expected to be an assessment of best-corrected visual acuity (BCVA), as assessed by the ETDRS scale with a non-inferiority margin of 4 letters.

The webcast presentation from the Company’s Ophthalmology Investor and Analyst Day is available here.

UBX1325 (foselutoclax) is designed as a novel and durable therapeutic option in diabetic macular edema (DME) that acts via a senolytic mechanism of action, with the potential to address shortcomings of the current standard of care, such as high treatment burden and sub-optimal response to treatment.

UNITY expects topline 24-week primary endpoint data in the first quarter of 2025 and 36-week data in the second quarter of 2025. The Phase 2b ASPIRE study in DME is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in a head-to-head comparison to aflibercept. More information about ASPIRE (NCT06011798) can be found here.

Third Quarter Financial Results

Cash, cash equivalents and marketable securities totaled $29.0 million as of September 30, 2024 compared with $43.2 million as of December 31, 2023. UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the third quarter of 2025.

Net loss for the three months ended September 30, 2024, was $6.5 million compared to $14.8 million for the three months ended September 30, 2023. Cash used in operations during the first, second and third quarters of 2024 was $15.0 million compared to $29.5 million during the first, second, and third quarters of 2023.

Research and development expenses decreased by $1.8 million, to $2.8 million for three months ended September 30, 2024, from $4.6 million for the three months ended September 30, 2023. The decrease was primarily due to $0.9 million in personnel costs due to our reduced headcount related to our reduction in force, $0.8 million in direct research and development expenses mainly due to the completion of the Phase 2 BEHOLD study of UBX1325 in patients with DME and the Phase 2 ENVISION study of UBX1325 in patients with AMD, and $0.1 million in operating costs due to reduced fixed assets depreciation and reduced office space.

General and administrative expenses decreased by $0.5 million, to $3.8 million for the three months ended September 30, 2024, from $4.3 million for the three months ended September 30, 2023. The decrease was primarily due to decreases of $0.5 million in personnel-related expenses due to reduced headcount and the reduction in bonus and severance amounts paid as compared to 2023 and $0.1 million in operating costs mainly from the continuation of sublease income generated from the East Grand property, partially offset by an increase of $0.1 million in professional fees and accounting service fees.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission on November 4, 2024, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Unity Biotechnology, Inc.
Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
 
 Three Months Ended  Nine Months Ended 
 September 30,  September 30, 
 2024  2023  2024  2023 
 (Unaudited)  (Unaudited) 
Operating expenses:           
Research and development$2,787  $4,632  $9,971  $16,828 
General and administrative 3,815   4,347   11,209   14,560 
Impairment of long-lived assets    5,602      5,602 
Total operating expenses 6,602   14,581   21,180   36,990 
Loss from operations (6,602)  (14,581)  (21,180)  (36,990)
Interest income 396   689   1,424   2,349 
Interest expense    (566)     (2,451)
Gain (loss) on warrant liability (215)  253   2,407   2,283 
Other income (expense), net (60)  (577)  (201)  (711)
Net loss (6,481)  (14,782)  (17,550)  (35,520)
Other comprehensive gain (loss)           
Unrealized gain (loss) on marketable debt securities 74   81   63   196 
Comprehensive loss$(6,407) $(14,701) $(17,487) $(35,324)
Net loss per share, basic and diluted$(0.38) $(1.01) $(1.04) $(2.46)
Weighted-average number of shares used in computing net loss per share, basic and diluted 16,849,283   14,598,218   16,816,706   14,446,672 
                


Unity Biotechnology, Inc.
Condensed Balance Sheets
(In thousands)
 
 September 30,  December 31, 
 2024  2023 
 (Unaudited)    
Assets     
Current Assets:     
Cash and cash equivalents$8,898  $19,803 
Short-term marketable securities 20,139   23,398 
Prepaid expenses and other current assets 1,226   3,404 
Total current assets 30,263   46,605 
Property and equipment, net 4,414   5,082 
Operating lease right-of-use assets 11,359   12,981 
Long-term restricted cash 896   896 
Other long-term assets 200   126 
Total assets$47,132  $65,690 
Liabilities and Stockholders’ Equity     
Current liabilities:     
Accounts payable$1,804  $1,380 
Accrued compensation 1,704   1,841 
Accrued and other current liabilities 5,276   4,619 
Total current liabilities 8,784   7,840 
Operating lease liability, net of current portion 20,698   23,539 
Warrant liability 3,506   5,913 
Total liabilities 32,988   37,292 
Commitments and contingencies     
Stockholders’ equity:     
Common stock 2   2 
Additional paid-in capital 516,006   512,773 
Accumulated other comprehensive gain 39   (24)
Accumulated deficit (501,903)  (484,353)
Total stockholders’ equity 14,144   28,398 
Total liabilities and stockholders’ equity$47,132  $65,690 
        

Media
Inizio Evoke Comms
Katherine Smith
katherine.smith@inizioevoke.com

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com


FAQ

What were UNITY Biotechnology's (UBX) Q3 2024 financial results?

UNITY reported a net loss of $6.5M, with cash position of $29.0M as of September 30, 2024. R&D expenses were $2.8M and G&A expenses were $3.8M.

When will UBX release topline data for UBX1325 in DME treatment?

UNITY expects to release 24-week primary endpoint data in Q1 2025 and 36-week data in Q2 2025.

What is UBX's cash runway based on Q3 2024 results?

UNITY believes its current cash position is sufficient to fund operations into the third quarter of 2025.

How did UBX's operating expenses change in Q3 2024 vs Q3 2023?

Operating expenses decreased with R&D costs reducing from $4.6M to $2.8M and G&A expenses declining from $4.3M to $3.8M.

Unity Biotechnology, Inc.

NASDAQ:UBX

UBX Rankings

UBX Latest News

UBX Stock Data

19.80M
16.63M
1.31%
20.55%
1.8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO